Elkedonia is developing a novel neuroplastogen for depression treatment, utilizing a precision medicine approach to induce neuroplasticity. This therapeutic candidate targets intracellular neuronal events with a unique mechanism of action, aiming to provide fast-acting relief without common antidepressant side effects.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
A significant portion of individuals with depression do not respond to existing treatments, and current therapies can carry risks of dependence, sedation, or psychotic effects. This limits treatment efficacy and patient quality of life, contributing to ongoing mental health challenges and increased suicide risk.
Solution
Elkedonia is developing a novel neuroplastogen designed to treat depression through a precision medicine approach. This therapeutic candidate targets intracellular events within neurons to induce neuroplasticity, offering a mechanism of action distinct from current treatments. The goal is to provide a fast-acting antidepressant that avoids the side effects commonly associated with other medications, enabling patients to achieve sustained relief and improved well-being. By focusing on a highly selective signaling pathway, Elkedonia aims to enhance treatment outcomes for patients with unmet needs in depression management.
Target Audience
The primary target audience includes patients diagnosed with depression, particularly those who have not responded to conventional treatments, and healthcare providers seeking advanced therapeutic options.
Features
- Novel neuroplastogen with a unique mechanism of action targeting intracellular neuronal events.
- Precision medicine approach focused on inducing neuroplasticity.
- Designed to avoid side effects such as dependence, sedation, or psychotic effects.
- Targets a highly selective signaling pathway within key brain circuits.
- Aims for fast-acting antidepressant effects.